Description du projet
Une analyse numérique de la sueur pour la surveillance de la santé à domicile
L’autogestion de la santé est une option intéressante pour les maladies chroniques telles que le diabète, les maladies cardiaques et respiratoires, ou pour la surveillance des personnes âgées à domicile. Le projet ONALABS, financé par l’UE, a mis au point un dispositif de surveillance portable non invasif qui combine plusieurs microcapteurs pour la surveillance continue et simultanée de paramètres physiques (fréquence cardiaque, saturation en oxygène, température de la peau, etc.) et biochimiques (taux de lactate, de glucose, etc.). Le caractère innovant de l’approche du projet tient au fait que ces paramètres soient mesurés à partir de la sueur et non du sang. Le dispositif portable dispose d’une interface conviviale et se connecte à des appareils mobiles pour le traitement des données. Les informations sont communiquées à l’hôpital, offrant aux médecins une mise à jour en temps quasi réel de l’état de santé des patients de tout âge, des nouveau-nés aux personnes âgées.
Objectif
Onalabs Healthcare was born as an ambitious project, technical and emotional focused in premature births where the patient is affected with Congenital Heart Disease (CHD). These patients need 24hour Intensive care monitoring for a period of at least 10 days where 25% of their total blood is extracted to measure 4 biomarkers (Lactate, pH, CO2 and Glucose). This generates pain and a high risk of vain damage as well as potential death due to infections.
Moreover, Heart and lung system problems are the first and fourth cause of death, respectively in Occidental territories, with more than 20 million deaths recorded in 2012. The solution that is offered by Onalabs with its product ‘Cardiopatch’ that addresses a potential market of 872M users. Our product does not rely on the extraction of blood to measure the 4 key parameters. We measure indirectly through a proven system of sweat analysis. This will allow us to also access the sport market and an additional 350M users in the sector of this that we target.
Targetting health care and sport, with a novel disruptive sensor we expect to drive a new market providing solutions providing high impact for society whilst growing to generate profits of 3.4M euros and employ 40 people by 2022
Champ scientifique
- natural sciencescomputer and information sciencesinternetinternet of things
- medical and health sciencesclinical medicinecardiologypaediatric cardiology
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- natural sciencescomputer and information sciencesdata sciencedata processing
- engineering and technologymedical engineeringwearable medical technology
Programme(s)
- H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
- H2020-EU.3.1.4. - Active ageing and self-management of health
- H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.1.6. - Health care provision and integrated care
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
08290 Barcelona
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.